Keystone Meeting on Microglia/Neurodegeneration: Here’s the Buzz
A dynamic joint meeting dispels some old tenets while charting new avenues for research, such as microglia from iPSCs.
6404 RESULTS
Sort By:
A dynamic joint meeting dispels some old tenets while charting new avenues for research, such as microglia from iPSCs.
Keystone Meeting on Microglia/Neurodegeneration: Here’s the Buzz Induced Microglia Make Debut at Keystone Symposium The THIK and Thin of Microglial Surveillance When a Microglia Is No Longer a Microglia Unbiased Screen Fingers TREM2 Ligands That Promote A
Three research groups turn induced pluripotent stem cells into what look like microglia.
Loose in the cytoplasm, TDP-43 heads straight for the neuronal powerhouses, sapping their ability to make energy.
Seeking strength in numbers, families gathered to swap stories and to learn about an upcoming DIAN-TU therapy trial geared specifically to their particular form of early onset AD.
Microglia and macrophages lacking the receptor consumed less amyloid in vitro, even when stimulated by anti-Aβ antibodies.
A bill approved by the U.S. House Committee on Appropriations would increase funding for Alzheimer’s by $350 million.
At Keystone, researchers report the discovery of ion channels that shed light on the machinations of the brain’s microglia.
Researchers are discovering that microglia not only respond dramatically to their environment, but they also can quickly lose their identity.
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
At Keystone, researchers also linked the receptor to microglial homeostasis and migration, and resolved lingering questions about TREM2’s role in plaque clearance.
Four researchers received awards totaling $350,000 for their contributions to Alzheimer’s research.
Antisense oligonucleotides can flip expression of tau from the three-repeat to the four-repeat form. These ASOs triggered tau aggregation and behavioral problems.
In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period. Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials Access: How to Bring People in ‘From the
Scientists pool samples and creatively mine the genomes of thousands of patients to find coding and non-coding variants that associate with the disease.